Recombinant APC Anti-PD-L1 antibody [28-8] (ab206967)
![Flow Cytometry - APC Anti-PD-L1 antibody [28-8] (ab206967)](https://www.abcam.com/ps/products/206/ab206967/Images/ab206967-312610-anti-pd-l1-antibody-28-8-allophycocyanin-flow-cytometry.jpg "Flow Cytometry - APC Anti-PD-L1 antibody [28-8] (ab206967)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- APC Rabbit monoclonal [28-8] to PD-L1
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: APC. Ex: 645nm, Em: 660nm
Overview
-
Product name
APC Anti-PD-L1 antibody [28-8]
See all PD-L1 primary antibodies -
Description
APC Rabbit monoclonal [28-8] to PD-L1 -
Host species
Rabbit -
Conjugation
APC. Ex: 645nm, Em: 660nm -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment within Human PD-L1 (extracellular). The exact sequence is proprietary.
Database link: Q9NZQ7 -
Positive control
- Flow Cyt: CHO-PDL1 cells
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot. Store at +4°C. Do Not Freeze. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 1% BSA -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
28-8 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Anti-PD-L1 antibody [28-8] (ab205921)
- Anti-PD-L1 antibody [28-8] - Low endotoxin, Azide free (ab209889)
- Alexa Fluor® 488 Anti-PD-L1 antibody [28-8] (ab209959)
- Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (ab209960)
- HRP Anti-PD-L1 antibody [28-8] (ab209961)
- PE Anti-PD-L1 antibody [28-8] (ab209962)
- Alexa Fluor® 555 Anti-PD-L1 antibody [28-8] (ab213358)
- Alexa Fluor® 568 Anti-PD-L1 antibody [28-8] (ab213359)
- Alexa Fluor® 594 Anti-PD-L1 antibody [28-8] (ab213360)
- FITC Anti-PD-L1 antibody [28-8] (ab224027)
- Anti-PD-L1 antibody [28-8] - BSA and Azide free (ab228413)
-
Isotype control
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab206967 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Flow Cyt | 1/500. The cellular localisation of this product has been verified in ICC/IF. |
Target
-
Function
Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production. -
Tissue specificity
Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes. -
Sequence similarities
Belongs to the immunoglobulin superfamily. BTN/MOG family.
Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
Cellular localization
Cell membrane and Endomembrane system. - Information by UniProt
-
Database links
- Entrez Gene: 29126 Human
- Omim: 605402 Human
- SwissProt: Q9NZQ7 Human
- Unigene: 521989 Human
-
Alternative names
- B7 H antibody
- B7 H1 antibody
- B7 homolog 1 antibody
see all
Images
-
Flow Cytometry - APC Anti-PD-L1 antibody [28-8] (ab206967)
Overlay histogram showing CHO-S (blue line) and CHO-PD-L1 transfected (red line) cells stained with ab206967.
The cells were incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab206967, 1/500 dilution) for 30 min at 22ºC.
Acquisition of >5,000 events were collected using a 17 mW red Helium-Neon laser (633nm) and 660/20 bandpass filter.
-
![APC Anti-PD-L1 antibody [28-8] (ab206967)](https://www.abcam.com/ps/products/206/ab206967/Images/ab206967-3-benefits-of-recombinant-antibodies.png)
APC Anti-PD-L1 antibody [28-8] (ab206967)
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
Certificate of Compliance
References (0)
ab206967 has not yet been referenced specifically in any publications.
